Urokinase-type plasminogen activator (uPA) in the neoplastic tissue and peripheral blood of bladder cancer patients

YANG Jinyi,LI Shao,ZhOU Rongxiang,et al.

　　Department of Urology,the Affiliated Hospital of Binzhou Medical College, Shandong 256603

　　Abstract　Objective　To study the uPA level in the neoplastic tissue and peripheral blood of bladder cancer patients.　Methods　51 cases of transitional cell bladder cancer were studied by means of enzyme-linked immunosorbent assay (ELISA).　Results　uPA content in neoplastic tissue of grade Ⅲ tumors was obviously higher than that in grade Ⅱ or grade Ⅰ tumors (P＜0.01) whereas there was no significant difference between grade Ⅰ and grade Ⅱ tumors.uPA content was also higher in the invasive tumors than the superficial ones (P＜0.05).There was no significant difference in peripheral blood uPA between bladder cancer patients and normal subjects.　Conclusions　uPA content in the neoplastic tissue might be a useful index of the degree of malignancy and invasiveness of transitional cell bladder cancinoma.

　　Key words　Bladder neoplasms　　Carcinoma　　Urokinase

　　近年來(lái)的研究表明，尿激酶型纖溶酶原激活劑（uPA）與腫瘤的侵襲和轉(zhuǎn)移密切相關(guān)。我們應(yīng)用酶聯(lián)免疫吸附實(shí)驗(yàn)（ELISA）檢測(cè)膀胱移行細(xì)胞癌患者血及腫瘤組織中uPA含量，以探討uPA在膀胱癌中的臨床應(yīng)用價(jià)值。

　　材料和方法

　　一、標(biāo)本收集

　　1996年8月～1998年5月本院收治膀胱癌51例，病理證實(shí)均為移行細(xì)胞癌。男38例，女13例，年齡24～72歲，平均61歲。按UICC標(biāo)準(zhǔn)分淺表性（PTa～PT1）36例，浸潤(rùn)性（PT2～PT4）15例。按WHO標(biāo)準(zhǔn)G1　14例，G2　24例，G3　13例。51例患者中23例行經(jīng)尿道電切術(shù)，19例行膀胱部分切除或加輸尿管再植術(shù)，9例行全膀胱切除術(shù)。所有病人術(shù)前及術(shù)后1周抽取前臂靜脈血2ml，離心后-20℃保留血清，另留取10例正常人血清做對(duì)照。經(jīng)尿道電切前用活檢鉗鉗取腫瘤標(biāo)本及肉眼觀察正常膀胱粘膜，開(kāi)放手術(shù)待標(biāo)本切下后，立即取腫瘤標(biāo)本及距腫瘤邊緣2cm以外肉眼觀正常之膀胱粘膜。另取非膀胱癌患者膀胱粘膜10例，其中前列腺增生癥7例，膀胱頸梗阻3例，平均年齡68歲。標(biāo)本取出后立即-70℃冰凍保存。